Exelixis | EXEL - Ordinary Share Capital


Exelixis reported $253.7M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
Bayer EUR 982.42M 0 Dec/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
Eisai JPY 282.11M 0 Mar/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Exelixis USD 253.7M 8.78M Mar/2026
Genmab DKK 61.62M 52K Dec/2025
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
MacroGenics USD 63.32M 60K Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Takeda JPY 1.58B 241K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Xencor USD 74.06M 2.19M Mar/2026